Feature

Can a nationwide liver paired donation program work?


 

Is a national liver paired donor program feasible?

While the UNOS pilot program offers financial assistance for expenses related to liver donation, some transplant surgeons are skeptical about the potential travel component of the pilot program.

The pilot program requires that the donor bring one support person if there is a need to travel for the surgery, but undergoing major abdominal surgery from a transplant team they are not familiar with may be stressful, said Peter Abt, MD, a transplant surgeon at the Hospital of the University of Pennsylvania and the Children’s Hospital of Philadelphia. “That’s a big ask,” he said, “and I’m not sure many potential donors would be up to that.”

John Roberts, MD, a transplant surgeon at the University of California, San Francisco, agreed that the travel component may put additional stress on the donor, but “if it’s the only way for the recipient to get a transplant, then the donor might be motivated,” he added.

Dr. Jackson remains optimistic. “Our experience so far has been that, yes, some people have been hesitant for things like traveling, but a lot of people who seem to be genuinely dedicated to the idea of living donation have been very enthusiastic,” she noted.

Dr. Leishman agreed that the travel aspect appears to one of the greatest barriers to participants entering the program but noted that a goal of the pilot program is to understand better what works - and what doesn’t – when considering a liver paired donation program on a national scale. “[Our] steering committee has put together a really nice framework that they think will work, but they know it’s not perfect. We’re going to have to tweak it along the way,” she said.

More information on the paired liver donation pilot program can be found on the UNOS website.

The sources interviewed for this article reported no financial conflicts of interest.

A version of this article first appeared on Medscape.com.

This article was updated 2/15/23.

Pages

Recommended Reading

Neighborhood factors contribute to liver cancer disparities in Texas
Clinician Reviews
Pervasive ‘forever chemical’ linked to liver cancer
Clinician Reviews
FDA okays terlipressin (Terlivaz) injection for hepatorenal syndrome
Clinician Reviews
COVID tied to spike in deaths in chronic liver disease with diabetes
Clinician Reviews
World falls short on HBV, HCV elimination targets
Clinician Reviews
Liver disease-related deaths rise during pandemic
Clinician Reviews
Bepirovirsen: Is a ‘functional cure’ for HBV on the horizon?
Clinician Reviews
How a cheap liver drug may be the key to preventing COVID
Clinician Reviews
Nonheavy alcohol use associated with liver fibrosis, NASH
Clinician Reviews
Strong support to provide DAA therapy to all patients with HCV
Clinician Reviews